Global offering nets $144.5mm for DBV Technologies

14:40 EST 31 Jan 2020 | Elsevier Business Intelligence

DBV Technologies SA (food allergy immunotherapies) netted $144.5mm through a global offering of 7.5mm ordinary shares: 4,535,...

Original Article: Global offering nets $144.5mm for DBV Technologies


More From BioPortfolio on "Global offering nets $144.5mm for DBV Technologies"

Quick Search

Relevant Topics

Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...